Press releaseGlobe Newswire
Palvella Therapeutics
PVLA · NASDAQ
$123.92+$0.96 (+0.78%)TodayMarket closed ·
Prev close $122.96
Latest news
- Press releaseGlobe Newswire
Palvella Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference
- Press releaseGlobe Newswire
Palvella Therapeutics Announces Three Poster Presentations Highlighting New Data in Microcystic Lymphatic Malformations and DSAP at Fall Clinical Dermatology 2026
- News
Palvella Therapeutics Receives Third Year Of Grant Funding From FDA Office Of Orphan Products Development For Phase 3 SELVA Trial And Ongoing Open-Label Extension Study Of QTORIN 3.9% Rapamycin Anhydrous Gel For Treatment Of Microcystic Lymphatic Malformations
- Press releaseGlobe Newswire
U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
- Press releaseBusiness Wire
Niagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth
- Press releaseGlobe Newswire
Palvella Therapeutics Appoints James R. Treat, M.D., Nationally Recognized Pediatric Dermatologist as Chief Medical Officer
- Press releaseGlobe Newswire
Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences
- Press releaseGlobe Newswire
Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
- Press releaseGlobe Newswire
Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
- News
Full Transcript: Palvella Therapeutics Q2 2026 Earnings Call
- Press releaseGlobe Newswire
Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- NewsAvi Kapoor
Hasbro, Utz Brands, Park Aerospace And Other Big Stocks Moving Higher On Tuesday
- Press releasePRNewswire
ResVita Bio Appoints John D. Doux, M.D., M.B.A., to Board of Directors
- News
Earnings Scheduled For March 31, 2026
- NewsAvi Kapoor
Nasdaq Gains Over 1%; Keurig Dr Pepper Earnings Top Views
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- NewsAvi Kapoor
Henry Schein, Vir Biotechnology, Ultra Clean Holdings And Other Big Stocks Moving Higher On Tuesday
- NewsAvi Kapoor
Dow Gains Over 100 Points; Home Depot Posts Upbeat Earnings
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- NewsAvi Kapoor
Dow Jumps 800 Points; ISM Manufacturing PMI Falls In December
- Press releaseGlobe Newswire
Palvella Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
- News
Earnings Scheduled For November 11, 2025
- Press releaseGlobe Newswire
Palvella Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
- NewsAvi Kapoor
This AeroVironment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
- Press releaseGlobe Newswire
Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
- Press releaseGlobe Newswire
Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.